View in EDS HTML Full Text PDF Full Text

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
Authors: Franek E; Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland., Gerstein HC; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada., Riddle MC; Department of Medicine, Oregon Health & Science University, Portland, Oregon., Nicolay C; Eli Lilly and Company, Indianapolis, Indiana., Hickey A; Eli Lilly and Company, Indianapolis, Indiana., Botros FT; Eli Lilly and Company, Indianapolis, Indiana., Loo LS; Eli Lilly and Company, Indianapolis, Indiana.
Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Sep; Vol. 24 (9), pp. 1753-1761. Date of Electronic Publication: 2022 May 30.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35546279
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Franek+E%22">Franek E</searchLink>; Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Gerstein+HC%22">Gerstein HC</searchLink>; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Riddle+MC%22">Riddle MC</searchLink>; Department of Medicine, Oregon Health & Science University, Portland, Oregon.<br /><searchLink fieldCode="AU" term="%22Nicolay+C%22">Nicolay C</searchLink>; Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Hickey+A%22">Hickey A</searchLink>; Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Botros+FT%22">Botros FT</searchLink>; Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Loo+LS%22">Loo LS</searchLink>; Eli Lilly and Company, Indianapolis, Indiana.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100883645%22">Diabetes, obesity & metabolism</searchLink> [Diabetes Obes Metab] 2022 Sep; Vol. 24 (9), pp. 1753-1761. <i>Date of Electronic Publication: </i>2022 May 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100883645 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1463-1326 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214628902%22">14628902 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Obes Metab <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35546279
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/dom.14760
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1753
    Titles:
      – TitleFull: Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Franek E
      – PersonEntity:
          Name:
            NameFull: Gerstein HC
      – PersonEntity:
          Name:
            NameFull: Riddle MC
      – PersonEntity:
          Name:
            NameFull: Nicolay C
      – PersonEntity:
          Name:
            NameFull: Hickey A
      – PersonEntity:
          Name:
            NameFull: Botros FT
      – PersonEntity:
          Name:
            NameFull: Loo LS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2022 Sep
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1463-1326
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Diabetes, obesity & metabolism
              Type: main
ResultId 1